Evolving Treatments for Advanced Renal Cell Carcinoma: ASCO 2023 and Beyond

Expert panelists review data presented at ASCO 2023 and surrounding meetings to elucidate the current treatment landscape of renal cell carcinoma.

EP. 1: Overview of First-Line Combination Therapy in Advanced Clear Cell RCC

June 26th 2023

Key opinion leaders on renal cell carcinoma management review first-line treatment options in the advanced clear cell disease space.

EP. 2: Factors in Selecting First-Line Therapy for Patients With Advanced Clear Cell RCC

June 26th 2023

A brief discussion on the patient and disease characteristics that help to inform selection of best therapy for patients with advanced clear cell renal cell carcinoma.

EP. 3: Advanced Clear Cell RCC: AE Profile of First-Line Combination Therapies

July 3rd 2023

Expert perspectives on the adverse event profiles of first-line combination therapies in the advanced clear cell renal cell carcinoma space.

EP. 4: Dosing Strategies With First-Line Therapy in Advanced Clear Cell RCC

July 3rd 2023

Panelists consider best practices in dosing while managing patients on first-line therapy for advanced clear cell renal cell carcinoma.

EP. 5: Selecting Therapy for a Real-World Patient With Clear Cell RCC

July 10th 2023

Centering discussion on a patient scenario of advanced clear cell renal cell carcinoma, panelists reflect on how they would approach selecting first-line therapy.

EP. 6: Rationale Behind Discontinuing IO Therapy in Clear Cell RCC

July 10th 2023

Focused discussion on the rationale behind discontinuing (or continuing) immunotherapy for patients with advanced clear cell renal cell carcinoma.

EP. 7: Second-Line Treatment Armamentarium in Clear Cell RCC

July 17th 2023

Comprehensive insight to treatment options available in the second-line setting of advanced clear cell renal cell carcinoma.

EP. 8: Relapsed/Refractory Clear Cell RCC: Novel Treatment Strategies

July 17th 2023

Switching their focus to relapsed/refractory advanced clear cell renal cell carcinoma, key opinion leaders review treatment options in this setting.

EP. 9: Selecting Optimal Therapy for Advanced Non-Clear Cell RCC

July 24th 2023

Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.

EP. 10: Renal Cell Carcinoma: Future Evolutions in Care

July 24th 2023

Shared insight on the evolving state of renal cell carcinoma management and hope for future growth in the treatment landscape.

EP. 11: Patient Profile Presentation: A 65-Year-Old Man with Advanced Clear Cell Renal Cell Carcinoma (RCC)

October 13th 2023

Robert Motzer, MD, presents the patient profile of a 65-year-old man diagnosed with clear cell RCC for discussion.

EP. 12: Available Treatment Options for Patients with Advanced RCC

October 13th 2023

Medical oncologists discuss a patient's surprising rapid decline after an initial diagnosis of clear cell RCC, emphasizing the efficacy of combination lenvatinib/pembrolizumab in similar patients.

EP. 13: Lenvatinib Plus Pembrolizumab for Firstline Treatment of Advanced RCC

October 20th 2023

Elizabeth Plimack, MD, and Robert Motzer, MD, explain their preferences between TKI-IO combination therapies for patients with advanced RCC considering efficacy, side effects, and specific patient factors.

EP. 14: Dosing Considerations for Combination Lenvatinib and Pembrolizumab in Patients with Advanced RCC

October 20th 2023

Experts detail their approaches to dosing combination lenvatinib and pembrolizumab for patients with advanced RCC, emphasizing individualized treatment for balanced efficacy and toxicity.

EP. 15: Managing Long-Term Toxicities of Combination Lenvatinib and Pembrolizumab in Advanced RCC

October 27th 2023

Drs Elizabeth Plimack and Robert Motzer discuss the long-term toxicities of combination lenvatinib/pembrolizumab in patients with advanced RCC, highlighting fatigue, GI discomfort, hand-foot syndrome, liver toxicity, thyroid toxicity, and proteinuria.

EP. 16: Key Takeaways in the Treatment of Advanced RCC From KCRS 2023

October 27th 2023

Robert Motzer, MD, and Elizabeth Plimack, MD, discuss clinical findings in the treatment of advanced RCC from the recent KCRS 2023 meeting, emphasizing the significance of circulating tumor cells, advances in imaging, and the potential of adjuvant therapies, particularly pembrolizumab.

EP. 17: Future Perspectives in the Treatment of Advanced RCC

November 3rd 2023

Oncologists discuss the need for more data on treatment duration in advanced RCC, emphasize the value of long-term patient follow-ups, and highlight the translational focus of the KCRS annual meeting, which combines clinical and early-stage research for renal cell carcinoma.